Loading
A phase 2/3 trial of Darovasertib, Crizotinib, Pembrolizumab in melanoma and uveal melanoma, run by IDEAYA Biosciences, active and no longer recruiting.
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma is a phase 2/3 interventional study registered as NCT05987332 by IDEAYA Biosciences, with 420 participants planned, started 2023-10-31 and due to reach its primary completion in 2027-01-15. Interventions recorded: IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab. Conditions listed: Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma, Melanoma.
Shares Darovasertib, IDEAYA Biosciences, Crizotinib, Uveal melanoma.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Uveal melanoma, Ipilimumab, Nivolumab, Melanoma.
Shares Darovasertib, Uveal melanoma, Melanoma.
Shares Uveal melanoma, Ipilimumab, Melanoma, Pembrolizumab.
Shares Ipilimumab, Nivolumab, Melanoma, Pembrolizumab.